Drugs / Idasanutlin
Idasanutlin
also known as
RO5503781 · IDASANUTLIN (RG-7388) · IDASANUTLINA · IDASANUTLINE · RG7388 · UNII-QSQ883V35U
Small molecule targets MDM2 via inhibition
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05952687 | Mar 2024 → Sep 2025 | atypical teratoid rhabdoid tumor | St. Jude Children's Research Hospital | Withdrawn | No outcome recorded |
| Phase 1 | NCT02828930 | Sep 2016 → Jun 2017 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02670044 | Mar 2016 → Dec 2020 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02407080 | Apr 2015 → Dec 2018 | acquired polycythemia vera, essential thrombocythemia | John Mascarenhas | Completed | No outcome recorded |
| Phase 1 | NCT01901172 | Aug 2013 → Jun 2015 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01773408 | Feb 2013 → Jun 2016 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01462175 | Nov 2011 → Jul 2014 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT04029688 | Jan 2020 → May 2024 | acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03850535 | Mar 2019 → Sep 2020 | acute myeloid leukemia | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03555149 | Sep 2018 → Sep 2022 | colorectal cancer | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03566485 | Jul 2018 → Dec 2020 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03158389 | May 2018 → Feb 2023 | adult glioblastoma | University Hospital Heidelberg | Completed | Mixed |
| Phase 1/2 | NCT03135262 | Jun 2017 → Apr 2020 | diffuse large B-cell lymphoma, follicular lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT02633059 | Dec 2015 → Jan 2021 | chromosome 17p deletion, plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT02624986 | Dec 2015 → May 2019 | non-Hodgkin lymphoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03287245 | Feb 2018 → Mar 2020 | acquired polycythemia vera | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02545283 | Dec 2015 → Apr 2020 | acute myeloid leukemia | Hoffmann-La Roche | Terminated | Missed primary |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | idasanutlin | “Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1...” PMID 31167802 ↗ Jun 201915“We evaluated idasanutlin-a new, potent murine double minute 2 antagonist-alone or with cytarabine in patients with r/r acute myeloid leukemia” PMID 33302031 ↗ Dec 2020 “Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.” PMID 34180037 ↗ Jun 2021 |
| Known as | IDASANUTLIN (RG-7388) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2402737 ↗ |
| Known as | IDASANUTLINA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2402737 ↗ |
| Known as | IDASANUTLINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2402737 ↗ |
| Known as | RG7388 | “Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1...” PMID 31167802 ↗ Jun 2019 |
| Known as | RO5503781 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01901172 ↗ |
| Known as | UNII-QSQ883V35U | ChEMBL registry synonym — accepted as the source's own label CHEMBL2402737 ↗ |
| Action | Inhibit | “idasanutlin inhibits the p53-MDM2 interaction” PMID 34180037 ↗ Jun 2021 |
| Modality | Small molecule | “a Small Molecule MDM2 Antagonist” NCT01462175 ↗ |
| Route | Oral | “administered orally” NCT01462175 ↗ |
| Target | MDM2 | “MDM2 antagonist” NCT01462175 ↗ |